{"id":2635,"date":"2018-05-09T23:58:09","date_gmt":"2018-05-09T18:28:09","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2635"},"modified":"2021-07-24T12:56:58","modified_gmt":"2021-07-24T07:26:58","slug":"takeda-buys-shire-deal-worth","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/takeda-buys-shire-deal-worth","title":{"rendered":"Takeda buys Shire in a deal worth USD 62 billion"},"content":{"rendered":"

Japan’s largest drugmaker Takeda<\/a> has successfully closed a deal worth USD 62 billion to buy another pharma giant Shire grabbing a place in the top 10 pharmaceutical company list. This is the biggest pharma acquisition of this year so far. Takeda<\/a> was trying to close a deal for quiet a long time and the news came on tuesday when the official announced that both the companies have made an agreement. The final valuation of Dublin based shire is set at USD 62.1 billion, excluding debt according to the officials. Including shire’s debt the buyout is worth USD 80 billion making it biggest deal ever signed by a japanese pharmaceutical company<\/a>. Takeda has a market value of around USD 33 billion and the deal has left the investors in fear of how to fund the acquisition. After this deal they will enter into the western markets opening new horizons for its growth.<\/p>\n","protected":false},"excerpt":{"rendered":"

Japan’s largest drugmaker Takeda has successfully closed a deal worth USD 62 billion to buy another pharma giant Shire grabbing a place in the top 10 pharmaceutical company list. This is the biggest pharma acquisition of this year so far. Takeda was trying to close a deal for quiet a long time and the news […]<\/p>\n","protected":false},"author":1,"featured_media":2733,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[204,349,1620,1261,1265,639,1622,1623,1621],"industry":[17225],"therapeutic_areas":[17239,17245,17228],"class_list":["post-2635","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-delveinsight","tag-latest-pharma-news","tag-pharma-acquisition","tag-pharma-consulting","tag-pharma-deals","tag-pharma-news","tag-takeda-acquire-shire","tag-takeda-shire-buyout","tag-takeda-shire-deal","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nTakeda buys Shire in a deal worth USD 62 billion- latest pharma deal<\/title>\n<meta name=\"description\" content=\"Takeda has successfully closed a deal worth USD 62 billion to buy another pharma giant Shire grabbing a place in the top 10 pharmaceutical company list.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/takeda-buys-shire-deal-worth\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda buys Shire in a deal worth USD 62 billion- latest pharma deal\" \/>\n<meta property=\"og:description\" content=\"Takeda has successfully closed a deal worth USD 62 billion to buy another pharma giant Shire grabbing a place in the top 10 pharmaceutical company list.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/takeda-buys-shire-deal-worth\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-09T18:28:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/15171018\/https_2F2Fs3-ap-northeast-1.amazonaws.com2Fpsh-ex-ftnikkei-3937bb42Fimages2F02F42F62F82F13588640-9-eng-GB2F20180406-takeda-pharmaceutical-02-logo-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda buys Shire in a deal worth USD 62 billion- latest pharma deal","description":"Takeda has successfully closed a deal worth USD 62 billion to buy another pharma giant Shire grabbing a place in the top 10 pharmaceutical company list.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/takeda-buys-shire-deal-worth","og_locale":"en_US","og_type":"article","og_title":"Takeda buys Shire in a deal worth USD 62 billion- latest pharma deal","og_description":"Takeda has successfully closed a deal worth USD 62 billion to buy another pharma giant Shire grabbing a place in the top 10 pharmaceutical company list.","og_url":"https:\/\/www.delveinsight.com\/blog\/takeda-buys-shire-deal-worth","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-05-09T18:28:09+00:00","article_modified_time":"2021-07-24T07:26:58+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/15171018\/https_2F2Fs3-ap-northeast-1.amazonaws.com2Fpsh-ex-ftnikkei-3937bb42Fimages2F02F42F62F82F13588640-9-eng-GB2F20180406-takeda-pharmaceutical-02-logo-scaled.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/takeda-buys-shire-deal-worth","url":"https:\/\/www.delveinsight.com\/blog\/takeda-buys-shire-deal-worth","name":"Takeda buys Shire in a deal worth USD 62 billion- latest pharma deal","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/takeda-buys-shire-deal-worth#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/takeda-buys-shire-deal-worth#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/15171018\/https_2F2Fs3-ap-northeast-1.amazonaws.com2Fpsh-ex-ftnikkei-3937bb42Fimages2F02F42F62F82F13588640-9-eng-GB2F20180406-takeda-pharmaceutical-02-logo-scaled.jpg","datePublished":"2018-05-09T18:28:09+00:00","dateModified":"2021-07-24T07:26:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Takeda has successfully closed a deal worth USD 62 billion to buy another pharma giant Shire grabbing a place in the top 10 pharmaceutical company list.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/takeda-buys-shire-deal-worth"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/takeda-buys-shire-deal-worth#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/15171018\/https_2F2Fs3-ap-northeast-1.amazonaws.com2Fpsh-ex-ftnikkei-3937bb42Fimages2F02F42F62F82F13588640-9-eng-GB2F20180406-takeda-pharmaceutical-02-logo-scaled.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/15171018\/https_2F2Fs3-ap-northeast-1.amazonaws.com2Fpsh-ex-ftnikkei-3937bb42Fimages2F02F42F62F82F13588640-9-eng-GB2F20180406-takeda-pharmaceutical-02-logo-scaled.jpg","width":2560,"height":1440,"caption":"takeda"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/15171018\/https_2F2Fs3-ap-northeast-1.amazonaws.com2Fpsh-ex-ftnikkei-3937bb42Fimages2F02F42F62F82F13588640-9-eng-GB2F20180406-takeda-pharmaceutical-02-logo-scaled.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">pharma acquisition<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">pharma deals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">takeda acquire shire<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">takeda shire buyout<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">takeda shire deal<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma acquisition<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">pharma deals<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">takeda acquire shire<\/span>","<span class=\"advgb-post-tax-term\">takeda shire buyout<\/span>","<span class=\"advgb-post-tax-term\">takeda shire deal<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on May 9, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on May 9, 2018 11:58 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2635"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2635\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2733"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2635"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2635"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}